Tafluprost 0.0015% is safe, effective and well-tolerated in routine clinical practice
To date, prostaglandin analogues (PGAs) have become the most common medical treatment worldwide to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. PGAs have a strong, sustained and stable IOPlowering effect and a generally well tolerated systemic safety profile.
Tafluprost 0.0015% is the first and only PGA that is available in a preservative-free formulation. We evaluated the efficacy, local tolerability and safety of preservative-free tafluprost 0.0015% (Taflotan) in a routine clinical setting.1